United-Guardian Reports Decline in Q3 2025 Earnings
United-guardian ( (UG) ) has released its Q3 earnings. Here is a breakdown of the information United-guardian presented to its investors.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
United-Guardian, Inc., a Delaware-based company, specializes in the manufacturing and marketing of specialty cosmetic ingredients, pharmaceutical products, and medical lubricants, operating primarily through its Guardian Laboratories division. In its latest earnings report for the quarter ending September 30, 2025, United-Guardian reported a decline in net sales to $2.26 million from $3.06 million in the same period last year, with net income also dropping to $268,441 from $865,484. Key financial metrics revealed a decrease in income from operations to $215,072 from $949,128, attributed to lower sales in cosmetic ingredients and increased operating expenses. Despite a challenging quarter, the company maintained a stable financial position with total assets of $12.18 million and retained earnings of $10.12 million. Looking ahead, United-Guardian remains focused on expanding its product lines and navigating global market challenges, including tariffs and supply chain issues, while anticipating the launch of its new Natrajel line in 2026.
